3D Printed Drugs Market
According to Intent Market Research, the 3D Printed Drugs Market is expected to grow from USD 92.5 million in 2023 at a CAGR of 26.2% to touch USD 472.5 million by 2030. The 3D Printed Drugs Market is dominated by key players such as GlaxoSmithKline (GSK), Merck & Co., 3D Systems Corporation, Aprecia Pharmaceuticals, BASF SE, Pfizer Inc., Stratasys Ltd., Materialise NV, Novartis AG, Trellisys Health, OrganoClick, Teva Pharmaceutical Industries Ltd., CAM Bioceramics B.V., Boehringer Ingelheim, Johnson & Johnson.